INNOVADERM CRO IS NOW INDERO.
READ THE ANNOUNCEMENT
Talk to us

Innovaderm Welcomes its New Vice-President, Biometrics

Ana Palijan, PhD

Ana Palijan, PhD

Director, Early Phase and Translational Research

Author picture

We are pleased to announce the addition of Pina D’Angelo to Innovaderm’s management team, as Vice-President, Biometrics. This recent hire supports our strategic commitment towards Biometrics, particularly important in the management of our ongoing phase 3 dermatology clinical programs. With her extensive experience as an expert in Biostatistics and Data Management, her participation in numerous meetings with Regulatory Bodies including the FDA and her cross therapeutic statistical expertise, Pina will be a valuable asset to our clients’ projects. We could not be more thrilled! Welcome to Innovaderm!

SHARE THIS POST

Subscribe to our newsletter.

Do not miss out on valuable insights and research updates. Join our scientific community today!

This field is for validation purposes and should be left unchanged.
Talk to us

Jeff Smith

Chef de la direction

Jeff Smith, Chef de la direction d’Indero Recherches, apporte près de 30 ans d’expérience dans l’industrie pharmaceutique et CRO, s’étant distingué par son leadership exceptionnel, sa vision stratégique et son innovation. L’expertise de Jeff couvre des opérations mondiales, la gestion de la croissance, ainsi que la promotion d’une culture d’entreprise collaborative. Ses atouts en matière de création de valeur, de gestion des partenaires et d’opérations CRO ont toujours contribué au succès dans ses fonctions précédentes. Sous la direction de Jeff, Indero continue d’étendre ses capacités, faisant progresser les connaissances médicales et les nouvelles thérapies en dermatologie et en rhumatologie.

Is Now

We are excited to announce that Innovaderm is rebranding our CRO division as Indero (in-dAIR-oh). This rebranding reflects our ongoing commitment to innovation and our expansion into the field of rheumatology, a therapeutic area closely linked to dermatology. As a dual-focus CRO specializing in both dermatology and rheumatology, this strategic decision marks a significant milestone for our organization, and we are eager to embark on this new chapter with our valued partners and clients. Additionally, our Clinical Research Unit (CRU) will keep the name Innovaderm and will continue to conduct dermatology studies.